Thill M, Zahn MO, Welt A, Nusch A, et al. Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry. Int J Cancer 2024 Dec 20. doi: 10.1002/ijc.35296.
PMID: 39707595